If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 9 of 9
A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Objective
A Study of Abbvie M22-947 in Patients with Relapsed Refractory Multiple Myeloma
Protocol No
ABBVIE-M22-947
Categories
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma
Objective
Testing the combination of one approved drug and two experimental drugs in patients with relapsed or refractory multiple myeloma
Protocol No
ALLIANCE-A062101
Categories
A Phase 3, Open-Label, Multicenter Study of I-124 evuzamitide as an Imaging Agent for the Diagnosis of Cardiac Amyloidosis using Positron Emission Tomography Computed Tomography (PET/CT)
Objective
REVEAL - Research with I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
Protocol No
ATTRALUS-REVEAL-AT01-301
Categories
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Protocol No
GRACELL-GC012F-CD19-BCMA-001
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination with Ruxolitinib in Participants with Newly Diagnosed Chronic Graft-Versus-Host Disease
Objective
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
Protocol No
INCYTE-INCA-34176-254
Categories
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial
Objective
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma Patients
Protocol No
UAB-21107-MASTER-2-MM
Categories
A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)
Objective
Prospective, Observational Study of Participants at Risk for CGVHD
Protocol No
INCYTE-MA-GVHD-401-THRIVE
Categories
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
Objective
CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Protocol No
C4THERAPEUTICS-CFT7455-1101
Categories
A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Mulitple Myeloma (CaMMouflage Trial)
Objective
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With RR MM
Protocol No
CARIBOU-CAMMOUFLAGE-CB-011A-MM